@article{a8658c1b7be340eda185d1d9d280600d,
title = "Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial",
keywords = "IL-13, atopic dermatitis, biologic therapy, efficacy, long-term, monoclonal antibody, open label, safety, tralokinumab",
note = "Publisher Copyright: {\textcopyright} 2022 American Academy of Dermatology, Inc.",
year = "2022",
month = oct,
doi = "10.1016/j.jaad.2022.07.019",
language = "English",
volume = "87",
pages = "815--824",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4",
}